Neoadjuvant chemotherapy in combination with surgery in the treatment of local advanced breast cancer

Zhao, Hongjing; Zhang, Jinying; Lu, Yanxia; Jin, Jihai

doi:10.12669/pjms.35.5.310

Cited by 6 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also in the study by Li, L, et al (2018) on breast cancer patients, the mean age of patients was higher than the mean age of the present study however, there was no significant difference between the two treatment groups in terms of mean age (13), which is also consistent with the results of the present study. The mean duration of surgery in the two treatment groups was 72 and 73 minutes while this time was obtained in the study of et al Haixia Zhao (2015) in two groups of 43 and 58 minutes (14), which is higher than the average duration of surgery in the present study.…”

Section: Discussioncontrasting

confidence: 63%

Efficacy and Safety of Concurrent Chemoradiotherapy with Docetaxel for Locally Advanced Breast Carcinoma after Modified Radical Mastectomy

2022

ircmj

View full text Add to dashboard Cite

Background: Breast cancer is a common term for a malignant tumor that arises from the epithelial component of the breast. Concurrent chemoradiotherapy’s efficacy and safety are controversial, considering the impact on patients' quality of life. Objectives: The aim of this study was investigating the efficacy and safety of concurrent chemoradiotherapy with docetaxel in locally advanced breast cancer who have received a modified radical mastectomy. Methods: A cohort of 110 female patients with locally advanced breast cancer were included in the present study and divided by chemoradiotherapy mode into a concurrent chemoradiotherapy group (n=58) and a sequential chemoradiotherapy group (n=52). Docetaxel was administered concurrently during radiotherapy in the concurrent group, whereas the sequential group underwent adjuvant radiotherapy 1-3 weeks after chemotherapy. Then, the two groups were compared with respect to clinical efficacy, levels of tumor markers across vascular endothelial growth factor (VEGF) and Carcinoembryonic antigen (CEA), adverse reactions, and the 3-year overall survival (OS) rate. Results: The results showed that the mean age, operation, evaluation of Post treatment VEGF (pg / mg) and Post treatment CEA (/g / L), effectiveness of treatment in two sequential and concurrent treatment groups was not significant The results showed that the amount of Prior treatment VGEF (pg / mg) and Post treatment VGEF (pg / mg) in the two groups were statistically significant difference. Which shows the positive effect of this treatment before and after the intervention. Comparison of survival time in the two groups did not show a significant difference. Conclusion: The chemotherapy protocol with a combination of cyclophosphamide, fluorouracil and epirubicin with concurrent docetaxel presented higher efficacy and prolonged the overall survival in locally advanced breast cancer patients who had undergone a radical mastectomy, while it did not significantly increase the toxicity.

show abstract

Section: Discussioncontrasting

confidence: 63%

Efficacy and Safety of Concurrent Chemoradiotherapy with Docetaxel for Locally Advanced Breast Carcinoma after Modified Radical Mastectomy

2022

ircmj

View full text Add to dashboard Cite

show abstract

“…Regarding surgery duration, two studies [25,27] favoured NACT and two studies [23,28] favoured the control group, but overall there was no difference between the two groups. These results are supported by Schaverien et al [47] in a prospective study on breast cancer patients which showed a non-significant trend towards a higher rate of multiple complications in patients treated with NACT compared to those who were not, and found no difference in surgery duration between the two groups.…”

Section: Discussionmentioning

confidence: 99%

“…The study was not included in the meta-analysis because follow-up was not defined. In terms of blood loss, two studies [25,27] favoured NACT while one study [38] favoured the control group. Although the difference in blood loss was found to be significant, favouring NACT over the control group, it should be interpreted cautiously as only three studies were included in the analysis providing a low power.…”

Section: Discussionmentioning

confidence: 99%

Impact of neoadjuvant chemotherapy on surgical complications in breast cancer: A systematic review and meta-analysis

Lorentzen

Heidemann

Möller

et al. 2022

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: The increased use of neoadjuvant chemotherapy (NACT) facilitates an increase in breastconserving surgery and immediate breast reconstruction. While NACT is considered to have the same oncological safety as adjuvant chemotherapy, evidence on the impact of NACT on surgical outcomes following breast surgery is unclear and varies across studies. The aim of this systematic review and metaanalysis was to assess the impact of NACT on surgical complications in breast cancer patients undergoing any kind of breast surgery. Methods: Database searches were conducted (March 26, 2021) to identify studies assessing the impact of NACT on postoperative complications. Studies were included if they compared a group of patients treated with NACT to a control group that was not, and if they reported at least one of our defined outcomes. Primary effect measures were odds ratios (ORs) and mean difference with a 95% confidence interval. Study quality was assessed by the Newcastle-Ottawa Scale. Results: Twenty-six studies comprising 134,191 patients were included. NACT was not associated with an increased complication rate for overall complications (OR: 1.13, 95% CI: 0.86 to 1.47, p ¼ 0.38), individual postoperative complications, nor surgery duration. There was a non-significant trend towards NACT increasing the risk of seroma, wound complications, skin or nipple necrosis, flap ischemia or loss, and implant loss. A significant difference in blood loss was found, favouring NACT (MD ¼ À75.85, 95% CI: -107.47 to À44.23, p < 0.00001). Heterogeneity was significant between the studies (I 2 >50%). Conclusion: Compared to a control group, NACT was not found to affect the surgical complications adversely.

show abstract

“…In addition, it is generally believed that pathological complete remission after neoadjuvant chemotherapy is closely related to the disease-free survival and overall survival of breast cancer patients. Patients with complete pathological remission often have a better prognosis [11,12].…”

Section: Introductionmentioning

confidence: 99%

The influence factors of clinical efficacy and prognosis of breast cancer patients treated with neoadjuvant chemotherapy

Tang

Zhang

2023

Preprint

View full text Add to dashboard Cite

Objective To investigate predictive indicators of clinical efficacy and prognosis of breast cancer patients treated with neoadjuvant chemotherapy. Methods 290 female patients with breast cancer who treated with neoadjuvant chemotherapy were enrolled in this study. The collected data including tumor position, tumor size, cTNM staging, LNR, pathological molecular types(including ER, PR, Her-2, Ki-67 and so on), neoadjuvant chemotherapy regimens, pathological complete response rate, postoperative treatment and survival time. Results Neoadjuvant chemotherapy curative effect was related to pausimenia, T staging, N staging, ER/PR and Ki-67(P < 0.05), N staging (OR = 0.041, 95% CI = 0.012 ~ 0.134) and Ki-67 (OR = 9.340, 95% CI = 1.770 ~ 49.286) were independent risk factors of pCR. Recurrence of metastases was related to T staging, LNR, Ki-67, ET regimen, postoperative chemotherapy and postoperation radiotherapy(P < 0.05), T staging (OR = 1.731, 95%CI = 1.244 ~ 2.408), LNR (OR = 2.726, 95%CI = 1.430 ~ 5.197) and Ki-67 (OR = 3.107, 95%CI = 1.395 ~ 6.920) were independent risk factors of recurrence of metastases. Patients with low Ki-67 expression, low LNR, T1 staging and T2 staging and N0/N1/N2 staging had a better prognosis. Conclusion Clinical efficacy and prognosis of breast cancer patients treated with neoadjuvant chemotherapy were related to cTNM staging, LNR, ER/PR and Ki-67.

show abstract

Neoadjuvant chemotherapy in combination with surgery in the treatment of local advanced breast cancer

Cited by 6 publications

References 20 publications

Efficacy and Safety of Concurrent Chemoradiotherapy with Docetaxel for Locally Advanced Breast Carcinoma after Modified Radical Mastectomy

Efficacy and Safety of Concurrent Chemoradiotherapy with Docetaxel for Locally Advanced Breast Carcinoma after Modified Radical Mastectomy

Impact of neoadjuvant chemotherapy on surgical complications in breast cancer: A systematic review and meta-analysis

The influence factors of clinical efficacy and prognosis of breast cancer patients treated with neoadjuvant chemotherapy

Contact Info

Product

Resources

About